Trial

Recruitment in time

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age (2023-ongoing)

A phase 2, randomized, double-blind, multicentre study to evaluate the safety and  immunogenicity of three different potency levels of V181 (Dengue quadrivalent vaccine rDENV∆30 [live, attenuated]) in healthy adults (2022-ongoing)

A phase 1a, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) in healthy adults (2022-ongoing)

Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults (2021 – ongoing)

A Phase 2b, open-label study to evaluate the safety, tolerability, and immunogenicity of vaccine candidate BNT162b2 in immunocompromised participants ≥ 2 years of age

A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID-19 in Healthy Individuals

Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019- COVID-19

Randomized, Controlled, Observer-Blind, Phase 2: Immunogenicity and Safety Study of VLA15, a Multivalent Recombinant OSPA Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years

A multi-centre safety registry for malaria patients treated with Eurartesim™

7

1 subject per month

A Phase 3, Open-Label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis with Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately from a Japanese Encephalitis Vaccine

A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection
Randomized, observer-blind, placebo-controlled, multicenter, multi-national, Phase III trial in 15.000 subjects

A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adults

A Phase III, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healthy Subjects Aged ≥10 toPhase III2009-015198-112323 subjects from July 2013 to December 2013 mostly subjects under 18 years old

Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51 (Ixiaro®, Jespect®) in a Pediatric Population in Non-Endemic Countries. Uncontrolled, Phase III Follow-Up Study

A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Seperately According to 1 or 2 Different Pre-exposure Prophylaxis Schedules to Healthy Adult Subjects

Enrolment 3 months;
138 subjects, 12 visits per subject,
1656 total visits in one year

A Phase IIIb, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Selected Travel Vaccines When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults

A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2012/2013, when Administered to Adult and Elderly Subjects

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults

A Phase 3 randomized, double-blind, placebo-controlled study os SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosis in subjects bitten by a tick

An Open Label, Uncontrolled Phase 4 Study to Assess the Safety and Imunnogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population

Immunogenicity and safety of the Japanese encephalitis vaccine IC51 (Ixiaro®, Jespect®) in a pediatric population in non-endemic countries. Uncontrolled, open-label phase 3 study

A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travellers’ Diarrhea Vaccine System in Travellers to Latin America

A Randomized, Single-Blind, Dose Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects from 6 Months to 17 Years of Age

A Randomized, Single-Blind, Dose Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted with MF59 (Fluad-H5N1), in Adult and Elderly Subjects

A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (intramuscular and intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant (MF59) admitted to Healthy Elderly Subjects > 65 Years